19,112 results match your criteria Hepatic Carcinoma Primary


RAE1 is a prognostic biomarker and is correlated with clinicopathological characteristics of patients with hepatocellular carcinoma.

BMC Bioinformatics 2022 Jun 24;23(1):252. Epub 2022 Jun 24.

Department of Biochemistry, Changzhi Medical College, Changzhi, 046000, Shanxi, China.

Background: Hepatocellular carcinoma (HCC) is a primary malignant tumor that accounts for approximately 90% of all cases of primary liver cancer worldwide. Microtubule alterations may contribute to the broad spectrum of resistance to chemotherapy, tumor development, and cell survival. This study aimed to assess the value of ribonucleic acid export 1 (RAE1), as a regulator of microtubules, in the diagnosis and prognosis of HCC, and to analyze its correlation with genetic mutations and pathways in HCC. Read More

View Article and Full-Text PDF

Aggregation-induced Emission (AIE) and Magnetic Resonance Imaging Characteristics for Targeted and Image-guided siRNA Therapy of Hepatocellular Carcinoma.

Adv Healthc Mater 2022 Jun 24:e2200579. Epub 2022 Jun 24.

Shanghai Institute of Transplantation, Shanghai, 200127, China.

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and remains a global health challenge. Small interfering RNA (siRNA) is a promising therapeutic modality that blocks multiple disease-causing genes without impairing cell structures. However, siRNA therapeutics still have off-target proportion and lack effective quantitative analysis method in vivo. Read More

View Article and Full-Text PDF

The state of therapy modalities in clinic for biliary tract cancer.

Front Biosci (Landmark Ed) 2022 Jun;27(6):185

Hepatic Surgery Centre, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430030 Wuhan, Hubei, China.

Biliary tract cancers (BTCs) include intrahepatic cholangiocarcinoma (iCCA), perihilar and distal cholangiocarcinoma (pCCA and dCCA), and gallbladder carcinoma based on the epithelial site of origin. BTCs are highly aggressive tumors associated with poor prognosis due to widespread metastasis and high recurrence. Surgery is the typical curative-intent treatment, yet the cornerstone of cure depends on the anatomical site of the primary tumor, and only a minority of patients (approximately 30%) has an indication necessitating surgery. Read More

View Article and Full-Text PDF

Aptamer-Based Triple Serum Fluorescence Intensity Assay: A Novel and Feasible Method for the Clinical Diagnosis of Primary Hepatic Carcinoma.

Front Oncol 2022 7;12:897775. Epub 2022 Jun 7.

Department of Gastroenterology, Jiangxi Institute of Gastroenterology and Hepatology, The First Affiliated Hospital of Nanchang University, Nanchang, China.

Background And Aims: Aptamers are artificial ligands that bind to biological targets with high specificity and affinity. We previously selected a group of aptamers against the serum of primary hepatic carcinoma (PHC) systematic evolution of ligands by exponential and enrichment (SELEX) method, and some of the aptamers were valuable for PHC diagnosis in polyacrylamide gel electrophoresis (PAGE) analysis. Here, we used aptamers to develop a novel method suitable for the clinical diagnosis of PHC. Read More

View Article and Full-Text PDF

Disseminated Primary Uterine Hepatoid Adenocarcinoma with α-Fetoprotein Production Demonstrated on F-FDG PET/CT.

Diagnostics (Basel) 2022 Jun 12;12(6). Epub 2022 Jun 12.

Department of Oncology, Rigshospitalet, Copenhagen University Hospital, 2100 Copenhagen, Denmark.

We present the F-Fluorodeoxyglucose (F-FDG) positron emission tomography/computed tomography (PET/CT) findings in a 57-year-old woman with post-menopausal bleeding diagnosed with hepatoid adenocarcinoma (HAC) with a primary tumour in the uterine corpus and a highly elevated level of serum-α-fetoprotein (S-AFP) at presentation. HAC is a variant of adenocarcinoma with hepatic differentiation representing a heterogeneous group of neoplasms that morphologically and immunphenotypically resemble hepatocellular carcinoma (HCC) but are of extrahepatic origin. Microscopically, they are usually poorly differentiated adenocarcinomas proliferating in solid sheets or in a trabecular or cord-like arrangement. Read More

View Article and Full-Text PDF

The Increasing Role of CT-Guided Cryoablation for the Treatment of Liver Cancer: A Single-Center Report.

Cancers (Basel) 2022 Jun 19;14(12). Epub 2022 Jun 19.

Unit of General Surgery 2, Clinica Chirurgica, Department of Medical, Surgical, and Experimental Sciences, University of Sassari, I-07100 Sassari, Italy.

Purpose: Cryoablation (CrA) is a minimally invasive treatment that can be used in primary and metastatic liver cancer. The purpose of this study was to assess the effectiveness of CrA in patients with hepatocellular carcinoma (HCC) and liver metastases.

Methods: We retrospectively evaluated the patients who had CrA for HCC or liver metastases between 2015 and 2020. Read More

View Article and Full-Text PDF

Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review.

Cancers (Basel) 2022 Jun 15;14(12). Epub 2022 Jun 15.

Polistudium SRL, 20135 Milan, Italy.

Acute porphyrias are a group of metabolic disorders resulting in defective porphyrin synthesis and reduced heme production, which carries a risk of malignancy. Porphyrias are inborn defects in the heme biosynthesis pathway resulting in neurovisceral manifestations and cutaneous photosensitivity attacks with multi-systemic involvement. Its estimated prevalence nears 5 per 100,000 patients worldwide. Read More

View Article and Full-Text PDF

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.

Biomedicines 2022 Jun 2;10(6). Epub 2022 Jun 2.

Department of Medical Oncology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.

Hepatocellular carcinoma (HCC) is an aggressive malignancy accounting for 90% of primary liver malignancies. Therapeutic options for HCC are primarily based on the baseline functional status, the extent of disease at presentation and the underlying liver function that is clinically evaluated by the Barcelona-Clinic Liver Cancer system and Child-Pugh score. In patients with advanced HCC, the United States Food and Drug Administration (US-FDA) approved systemic therapies include the combination of atezolizumab-bevacizumab, sorafenib, and lenvatinib in the first line setting while cabozantinib, regorafenib, ramucirumab (in patients with alfa-fetoprotein [AFP] > 400 ng/mL), pembrolizumab, nivolumab, and nivolumab-ipilimumab combination are reserved for patients who progressed on sorafenib. Read More

View Article and Full-Text PDF

Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.

Authors:

Lancet Gastroenterol Hepatol 2022 Jun 20. Epub 2022 Jun 20.

Background: Combating viral hepatitis is part of the UN Sustainable Development Goals (SDGs), and WHO has put forth hepatitis B elimination targets in its Global Health Sector Strategy on Viral Hepatitis (WHO-GHSS) and Interim Guidance for Country Validation of Viral Hepatitis Elimination (WHO Interim Guidance). We estimated the global, regional, and national prevalence of hepatitis B virus (HBV), as well as mortality and disability-adjusted life-years (DALYs) due to HBV, as part of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. This included estimates for 194 WHO member states, for which we compared our estimates to WHO elimination targets. Read More

View Article and Full-Text PDF

Prognostic factors for patients with mass-forming intrahepatic cholangiocarcinoma: A case series of 68 patients.

World J Gastrointest Surg 2022 May;14(5):442-451

Faculty of Hepato-Pancreato-Biliary Surgery, Institute of Hepatobiliary Surgery of Chinese PLA, Key Laboratory of Digital Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, China.

Background: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer in humans after hepatocellular carcinoma and a rare epithelial malignancy that results in a poor prognosis. According to the Liver Cancer Study Group of Japan classification, ICC can be divided into three types: Mass-forming (MF) type, periductal-infiltrating (PI) type, and intraductal-growth type. The MF type is the most common, accounting for 57. Read More

View Article and Full-Text PDF

Harnessing natural-product-inspired combinatorial chemistry and computation-guided synthesis to develop -glycan modulators as anticancer agents.

Chem Sci 2022 Jun 19;13(21):6233-6243. Epub 2022 Apr 19.

Genomics Research Center, Academia Sinica 128, Section 2, Academia Road Taipei 11529 Taiwan

Modulation of -glycosylation using human Golgi α-mannosidase II (α-hGMII) inhibitors is a potential anticancer approach, but the clinical utility of current α-hGMII inhibitors is limited by their co-inhibition of human lysosomal α-mannosidase (α-hLM), resulting in abnormal storage of oligomannoses. We describe the synthesis and screening of a small library of novel bicyclic iminosugar-based scaffolds, prepared natural product-inspired combinatorial chemistry (NPICC), which resulted in the identification of a primary α-hGMII inhibitor with 13.5-fold selectivity over α-hLM. Read More

View Article and Full-Text PDF

Preoperative PDW levels predict pulmonary metastasis in patients with hepatocellular carcinoma.

BMC Cancer 2022 Jun 21;22(1):683. Epub 2022 Jun 21.

Department of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, 150081, China.

Background: In hepatocellular carcinoma (HCC), pulmonary metastasis (PM) after hepatectomy is associated with poor clinical outcomes. The crucial phases of tumour cell proliferation, angiogenesis, and metastasis all entail platelet activation. In HCC, platelet distribution width (PDW) suggests platelet size changes and predicts a worse prognosis. Read More

View Article and Full-Text PDF

Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study.

Hepatol Int 2022 Jun 21. Epub 2022 Jun 21.

Department of Oncology and Hematology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, 646000, China.

Background: The optimal locoregional treatment for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT) is unclear. This study aimed to investigate the efficacy of Gamma knife radiosurgery (GKR) versus transcatheter arterial chemoembolization (TACE) in HCC patients with PVTT.

Methods: This retrospective study included 544 HCC patients with PVTT (GKR, 202; TACE, 342). Read More

View Article and Full-Text PDF

Quantitative dual-energy computed tomography texture analysis predicts the response of primary small hepatocellular carcinoma to radiofrequency ablation.

Hepatobiliary Pancreat Dis Int 2022 Jun 7. Epub 2022 Jun 7.

Department of Radiology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.

Background: Radiofrequency ablation (RFA) is one of the effective therapeutic modalities on patients with hepatocellular carcinoma (HCC). However, there is no proper method to evaluate the HCC response to RFA. This study aimed to establish and validate a clinical prediction model based on dual-energy computed tomography (DECT) quantitative-imaging parameters, clinical variables, and CT texture parameters. Read More

View Article and Full-Text PDF

Optimizing the Suboptimal: Hepatocellular Carcinoma Surveillance Guide for Primary Care Practitioners Based on a Medscape Education Online Activity.

Authors:
Richard Finn

J Fam Pract 2022 May;71(4 Suppl):S2-S8

The goal of this activity is to update primary care practitioners (PCPs) on risk factors and trends in hepatocellular carcinoma (HCC) development, as well as guideline recommendations and best practices for collaborating with specialists in HCC surveillance. Read More

View Article and Full-Text PDF

Clinical Benefits of Direct-acting Antivirals Therapy in Hepatitis C Virus Patients with Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

J Gastroenterol Hepatol 2022 Jun 20. Epub 2022 Jun 20.

Department of General Surgery, Qilu Hospital, Shandong University, Jinan, China.

Purpose: The purpose of the present study was to evaluate the effect of direct-acting antivirals (DAAs) therapy on the clinical outcomes of hepatitis C virus (HCV) patients with hepatocellular carcinoma (HCC).

Methods: We searched multiple electronic databases from database inception to June 14, 2021. Meta-analyses were performed separately for HCC recurrence and overall survival (OS). Read More

View Article and Full-Text PDF

Radiomics for the detection of microvascular invasion in hepatocellular carcinoma.

World J Gastroenterol 2022 May;28(20):2176-2183

Department of Radiology, Huashan Hospital, Fudan University, Shanghai 200040, China.

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, accounting for about 90% of liver cancer cases. It is currently the fifth most common cancer in the world and the third leading cause of cancer-related mortality. Moreover, recurrence of HCC is common. Read More

View Article and Full-Text PDF

Cytotoxic capability and the associated proteomic profile of cell-free coelomic fluid extracts from the edible sea cucumber on HepG2 liver cancer cells.

EXCLI J 2022 25;21:722-743. Epub 2022 Apr 25.

Dipartimento di Scienze e Tecnologie Biologiche, Chimiche e Farmaceutiche (STEBICEF), Università di Palermo, Palermo, Italy.

Hepatocellular carcinoma (HCC) is an aggressive cancer histotype and one of the most common types of cancer worldwide. The identification of compounds that might intervene to restrain neoplastic cell growth appears imperative due to its elevated overall mortality. The marine environment represents a reservoir rich in bioactive compounds in terms of primary and secondary metabolites produced by aquatic animals, mainly invertebrates. Read More

View Article and Full-Text PDF

Prospective validation to prevent symptomatic portal vein thrombosis after liver resection.

World J Hepatol 2022 May;14(5):1016-1024

Department of Digestive Surgery, Nihon University School of Medicine, Tokyo 1738610, Japan.

Background: Portal vein thrombosis (PVT) after liver resection is rare but can lead to life-threatening liver failure. This prospective study evaluated patients using contrast-enhanced computed tomography (E-CT) on the first day after liver resection for early PVT detection and management.

Aim: To evaluate patients by E-CT on the first day after liver resection for early PVT detection and immediate management. Read More

View Article and Full-Text PDF

A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma.

Front Immunol 2022 2;13:879452. Epub 2022 Jun 2.

Department of General Surgery, Chonnam National University Medical School and Chonnam National University Hwasun Hospital, Hwasun, South Korea.

Background: To explore the feasibility and safety of natural killer (NK) cell therapy in HCC, we performed a prospective, open-label, phase I trial to evaluate the synergistic effect of locoregional high-dose autologous NK cell therapy in combination with hepatic arterial infusion chemotherapy (HAIC).

Methods: Patients with locally advanced HCC who were refractory to the standard treatment were eligible for this study. Patients received expanded and activated NK cells for 5 consecutive days in a dose-escalating manner (dose 2. Read More

View Article and Full-Text PDF

Combination of Radiofrequency Ablation With Resiquimod to Treat Hepatocellular Carcinoma Inflammation of Tumor Immune Microenvironment and Suppression of Angiogenesis.

Front Oncol 2022 2;12:891724. Epub 2022 Jun 2.

Department of Surgery, The Fourth Affiliated Hospital, International Institutes of Medicine, Zhejiang University School of Medicine, Yiwu, China.

Background: Radiofrequency ablation (RFA) destroys tumors through hyperthermic injury, which induces the release of immunogenic intracellular substrates and damages associated molecular patterns (DAMPs) to evoke a systemic immune response, but its therapeutic effect is limited. This study aimed to combine RFA with an immunomodulator, resiquimod (R848), to enhance the RFA-induced antitumor immunity.

Methods: We performed RFA on subcutaneous tumors in immunocompetent mice and intraperitoneally injected R848 to observe the efficacy of the combination therapy. Read More

View Article and Full-Text PDF

Gemcitabine Plus Cisplatin Versus Non-Gemcitabine and Cisplatin Regimens as Neoadjuvant Treatment for Cholangiocarcinoma Patients Prior to Liver Transplantation: An Institution Experience.

Front Oncol 2022 2;12:908687. Epub 2022 Jun 2.

Department of Internal Medicine, Weill Cornell Medical College, New York, NY, United States.

Background: Cholangiocarcinoma management is constantly being updated in view of existing evidence in order to establish practice guidelines and consensus statements. However, the available treatment guidelines to optimize outcomes for cholangiocarcinoma patients who require liver transplantation are still controversial. This study contributing to the cholangiocarcinoma care field by investigating a new promising neoadjuvant therapy that might be help to grant the liver transplant option to the patients with cholangiocarcinoma. Read More

View Article and Full-Text PDF

Ginsenoside Rg3 and sorafenib combination therapy relieves the hepatocellular carcinomaprogression through regulating the HK2-mediated glycolysis and PI3K/Akt signaling pathway.

Bioengineered 2022 May;13(5):13919-13928

Department of Oncology, The Second People's Hospital of Kunshan, Suzhou, China.

Hepatocellular carcinoma (HCC) is the most common pathological type of primary hepatic carcinoma. This study investigated the effects of ginsenoside Rg3 (Rg3) and sorafenib (SFN) combination therapy on HCC progression. The HCC-related data were obtained from TCGA database, and the data of HK2 mRNA, clinicopathological features, and survival outcomes were extracted using R Programming 4. Read More

View Article and Full-Text PDF

Regular Aspirin Use Is Associated with a Reduced Risk of Hepatocellular Carcinoma (HCC) in Chronic Liver Disease: a Systematic Review and Meta-analysis.

J Gastrointest Cancer 2022 Jun 18. Epub 2022 Jun 18.

Department of Gastroenterology/Hepatology, Lyell McEwin Hospital, Haydown Road, Elizabeth Vale, SA, 5112, Australia.

Purpose: Aspirin reduces the incidence of various gastrointestinal (GI) malignancies. This meta-analysis assessed the efficacy and safety of regular aspirin use on the incidence of hepatocellular carcinoma (HCC) in patients with chronic liver disease.

Methods: Electronic reference databases were searched for studies in patients with chronic liver disease exposed to aspirin. Read More

View Article and Full-Text PDF

Lens culinaris agglutinin inhibits human hepatoma cell migration via mannose and fucose-mediated ERK1/2 and JNK1/2/3 signalling pathway.

Mol Biol Rep 2022 Jun 18. Epub 2022 Jun 18.

Chongqing Engineering Research Center of Medical Electronics and Information Technology, College of Bioinformatics, Chongqing University of Posts and Telecommunications, 400065, Chongqing, China.

Background: Hepatocellular carcinoma (HCC) is the main types of primary liver cancer, which shows some abnormal glycosylation, such as the increase of fucose. Lens culinaris agglutinin (LCA), a natural plant lectin that can bind to mannose and fucose, has been reported to be antiproliferative to may tumors. However, the effect of LCA on the vitality and migration ability of human hepatoma cells is not demonstrated. Read More

View Article and Full-Text PDF

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.

Front Oncol 2022 31;12:909035. Epub 2022 May 31.

Department of Oncology, Jiangsu Province Hospital, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.

Purpose: Immune checkpoint inhibitors plus antiangiogenic tyrosine kinase inhibitors may offer a first-line treatment for advanced hepatocellular carcinoma (HCC). In this phase 2 trial [registered with clinicaltrials.gov (NCT04052152)], we investigated the safety and efficacy of first-line anti-PD-1 antibody sintilimab plus antiangiogenic TKI anlotinib for advanced HCC. Read More

View Article and Full-Text PDF

Identification of an Endoplasmic Reticulum Stress-Related Gene Signature to Evaluate the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma.

Front Genet 2022 27;13:850200. Epub 2022 May 27.

Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.

Liver cancer is the sixth most frequently diagnosed primary malignancy and ranks as the third leading cause of cancer-related death worldwide in 2020. ER stress also plays a vital role in the pathogenesis of malignancies. In the current study, we aimed to construct an endoplasmic reticulum stress-related genes (ERGs) signature to predict the overall survival (OS) of patients with HCC. Read More

View Article and Full-Text PDF

A Hybrid Particle-Flow CFD Modeling Approach in Truncated Hepatic Arterial Trees for Liver Radioembolization: A Patient-specific Case Study.

Front Bioeng Biotechnol 2022 30;10:914979. Epub 2022 May 30.

IBiTech-Biommeda, Department of Electronics and Information Systems, Ghent University, Ghent, Belgium.

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. At its intermediate, unresectable stage, HCC is typically treated by local injection of embolizing microspheres in the hepatic arteries to selectively damage tumor tissue. Interestingly, computational fluid dynamics (CFD) has been applied increasingly to elucidate the impact of clinically variable parameters, such as injection location, on the downstream particle distribution. Read More

View Article and Full-Text PDF

FUNDC2 promotes liver tumorigenesis by inhibiting MFN1-mediated mitochondrial fusion.

Nat Commun 2022 Jun 17;13(1):3486. Epub 2022 Jun 17.

The MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, 310058, China.

Mitochondria generate ATP and play regulatory roles in various cellular activities. Cancer cells often exhibit fragmented mitochondria. However, the underlying mechanism remains elusive. Read More

View Article and Full-Text PDF

lncRNA MALAT1 promotes HCC metastasis through the peripheral vascular infiltration via miRNA-613: a primary study using contrast ultrasound.

World J Surg Oncol 2022 Jun 16;20(1):203. Epub 2022 Jun 16.

Department of Oncology, the Second Affiliated Hospital of Qiqihar Medical College, Qiqihar, 161006, China.

Background: This study aimed to explore the specific pathogenesis of lncRNA MALAT1 promoting the invasion and metastasis of hepatocellular carcinoma (HCC) through peripheral blood vessels by regulating the expression of miRNA-613 molecule.

Methods: The data of 60 HCC metastatic patients and 60 HCC non-metastatic patients detected by the contrast-enhanced ultrasound (CEUS) in the Second Affiliated Hospital of Qiqihar Medical College from January 2020 to June 2021 were collected, as well as postoperatively retained HCC tissues and paired paracancer tissues (5 cm laterally from the edge of the cancer area), to study the changes of microangiogenesis in HCC tissues with CEUS. The correlation between CEUS grading and lncRNA MALAT1 in patients with HCC was analyzed through Pearson correlation analysis, lncRNA MALAT1 and miRNA-613 in HCC tissues of patients with HCC were detected by qRT-PCR, followed by the bioinformatic analysis for the relationship between lncRNA MALAT1 and miRNA-613. Read More

View Article and Full-Text PDF